Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 10Recruiting 6Withdrawn 3Terminated 2Unknown 1Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 1296Carcinoma, Non-Small-Cell Lung 793Neoplasms 787Colorectal Neoplasms 760Stomach Neoplasms 587Carcinoma, Hepatocellular 581Prostatic Neoplasms 514Lung Neoplasms 466Pancreatic Neoplasms 421Rectal Neoplasms 336Recurrence 314Neoplasm Metastasis 308Leukemia, Myeloid, Acute 293Colonic Neoplasms 283Multiple Myeloma 280Lymphoma 276Esophageal Neoplasms 273Uterine Cervical Neoplasms 272Ovarian Neoplasms 263Melanoma 246Head and Neck Neoplasms 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 210Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 187Nasopharyngeal Carcinoma 182Leukemia 173Lymphoma, Non-Hodgkin 171Liver Neoplasms 165Glioblastoma 160Polycystic Ovary Syndrome 157

Interventions

Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Interventional × Hearing Loss × Clear all
NCT04291209 2023-09-06

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Sunnybrook Health Sciences Centre

Phase 1/2 Unknown
80 enrolled

Deafness, Ear Diseases, Hearing Loss, Sensorineural, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡